Esperion Therapeutics, Inc.

NASDAQ:ESPR

Biotechnology

Healthcare
$3.18 -0.32%

+$0.00 today

Market cap
$661.15M
Beta
1.07
P/E (TTM)
-107.3
EPS (TTM)
-$0.03
52W Low $0.95High $4.18

Volume 0.00M

Average 12.29M

ESPR Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Esperion Therapeutics, Inc.NASDAQ: ESPR

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow turns positive

Q1 FY2026 financing cash flow was $16.22M, compared with -$7.5M a year earlier. Trailing-twelve-month financing cash flow was $59.9M. Over 3 fiscal years it compounded at +3.5% a year.

Context

  • Financing cash flow amounted to 9.0% of revenue in FY2025, down 17.0 pp from a year earlier.
  • Financing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly financing cash flow holds near $16.22M or moves back toward the trailing-twelve-month quarterly average of $14.98M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$16.22M-46.2% QoQ
Last fiscal yearDec 2025
$36.18M-58.2% YoY
LTMMar 2026
$59.9M+615.4% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+316.2%——
1 year-58.2%——
3-year CAGR+3.5%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
36.18M USD
Year-over-year change
-58.2%
4-year CAGR
-39.4%

Financing Cash Flow vs competitors

How ESPR compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +615.4% is the highest of 10, against a peer median of +60.2%.
  • Financing cash flow amounts to 14.3% of revenue for ESPR, versus a peer median of 47.0%.
ESPR Competitors
Financing Cash Flow for ESPR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$256.78M USD-1.3%+662.8%—
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$226.9M USD+360.2%——
EBSEmergent BioSolutions Inc.LTM Mar 2026$147.6M USD-36.1%—21.8%
RGNXREGENXBIO Inc.LTM Mar 2026$108.93M USD+421.9%—124.0%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$86.39M USD+284.0%+107.0%171.9%
ABSIAbsci CorporationLTM Mar 2026$70.71M USD+60.2%+172.5%3851.4%
OFIXOrthofix Medical Inc.LTM Mar 2026$63.96M USD+123.6%+116.0%7.7%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$59.9M USD+615.4%+3.5%14.3%
SNDLSNDL Inc.LTM Mar 2026CA$50.85M CAD-20.7%+9.2%5.4%
SIGASIGA Technologies, Inc.LTM Mar 2026$44.12M USD+1.5%-1.8%47.0%
Peer median (excluding ESPR) —+60.2%+111.5%47.0%

Competitors are the stored peer set for ESPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(269.11M)(233.66M)(209.25M)(51.75M)(22.68M)
Depreciation & Amortization612K500K164K63K105K
Deferred Income Tax00000
Stock-Based Compensation24.31M15.22M11.96M11.99M9.87M
Change in Working Capital(52.51M)(3.37M)13.68M(60.53M)(14.64M)
Accounts Receivables(10.55M)(10.8M)(14.77M)(31.65M)(60.05M)
Inventory(18.26M)(807K)(30.42M)(28.87M)(10.63M)
Accounts Payables(34.1M)5.6M8.68M12.43M20.92M
Other Working Capital10.39M2.63M50.18M(12.45M)35.12M
Other Non-Cash Items32.89M46.49M47.96M76.57M14.26M
Operating Cash Flow(263.81M)(174.83M)(135.49M)(23.65M)(13.09M)
Capital Expenditures000(317K)0
Acquisitions (Net)00000
Purchases of Investments(50.48M)(59.9M)000
Sales of Investments068M42.5M00
Other Investing Activities00000
Investing Cash Flow(50.48M)8.1M42.5M(317K)0
Debt Repayment(440K)(58.24M)(15.51M)35.01M(54.91M)
Common Stock Issued218.69M90.85M56.88M91.19M98.35M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities49.98M0(6.42M)(39.72M)(7.26M)
Financing Cash Flow268.22M32.61M50.46M86.48M36.18M
Effect of Forex Changes00000
Net Change in Cash(46.07M)(134.12M)(42.53M)62.51M23.09M
Free Cash Flow(263.81M)(174.83M)(135.49M)(23.97M)(13.09M)

Esperion Therapeutics, Inc.

NASDAQ:ESPR

Intrinsic Alpha fair value

Locked

Current Price

$3.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.